JP2017114851A - キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用 - Google Patents
キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用 Download PDFInfo
- Publication number
- JP2017114851A JP2017114851A JP2016234432A JP2016234432A JP2017114851A JP 2017114851 A JP2017114851 A JP 2017114851A JP 2016234432 A JP2016234432 A JP 2016234432A JP 2016234432 A JP2016234432 A JP 2016234432A JP 2017114851 A JP2017114851 A JP 2017114851A
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- xanthine oxidase
- compound
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010093894 Xanthine oxidase Proteins 0.000 title claims abstract description 45
- 102100033220 Xanthine oxidase Human genes 0.000 title claims abstract description 45
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 title claims abstract description 19
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 238000012544 monitoring process Methods 0.000 claims abstract description 6
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 5
- 201000005569 Gout Diseases 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- -1 β-carboline alkaloid compound Chemical class 0.000 claims description 23
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 20
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 20
- 229940116269 uric acid Drugs 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 9
- 150000007942 carboxylates Chemical group 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- USBWYUYKHHILLZ-UHFFFAOYSA-N flazin Chemical compound O1C(CO)=CC=C1C1=NC(C(O)=O)=CC2=C1NC1=CC=CC=C12 USBWYUYKHHILLZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003064 xanthine oxidase inhibitor Substances 0.000 abstract description 12
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 abstract description 9
- 239000000047 product Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940075420 xanthine Drugs 0.000 description 6
- 108010092464 Urate Oxidase Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 240000008467 Oryza sativa Japonica Group Species 0.000 description 1
- 235000005043 Oryza sativa Japonica Group Nutrition 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
- C12Y117/03—Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
- C12Y117/03002—Xanthine oxidase (1.17.3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/9029—Oxidoreductases (1.) acting on -CH2- groups (1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
【解決手段】式(I)で表されるβ−カルボリンアルカロイド構造を有するキサンチンオキシダーゼ阻害剤の使用。
(R1はH、−CO2H等、R2はメチル、−CH2COOCH3等)
【選択図】なし
Description
カラム:COSMOSIL 5C18−AR−II(内径:4.6mm×25cm)、
移動相:アセトニトリル(100%):リン酸(0.085%)=30:70、
流量:1ml/分、
フラジンの保持時間は約12.5分である。
フラジンのUV/VIS吸収スペクトルは196.1nm、290.4nm及び362.4nmである。
キサンチンオキシダーゼ阻害活性を下記のように測定した。初めに様々な濃度(0.625mg/ml、1.25mg/ml、2.5mg/ml、5.0mg/ml、10.0mg/ml及び20.0mg/ml)のフラジンサンプルを準備した。次いで、キサンチンオキシダーゼ阻害活性を下記の手順でHPLCにより測定した。反応管にて、880μlのキサンチン(100mM PBS中、50μg/ml)及び40μlの50mM PBS又は40μlのフラジンサンプルを予め混合し、80μlのキサンチンオキシダーゼ(0.1U)を添加することで、反応を開始した。反応物を30℃で30分間インキュベートした後、等量の無水エタノールを添加することで、反応を終了させた。終了後の反応物を0.22μm径の膜フィルターに通して濾過し、反応物におけるキサンチンの含量をHPLCによって分析した。サンプルのキサンチンオキシダーゼ阻害活性を下記のように算出した:
XOI(%)=100×([キサンチン]反応後サンプル−[キサンチン]反応後対照)/([キサンチン]初期−[キサンチン]反応後対照)
2つのフラジン試験サンプル(サンプルA及びサンプルB)を準備し、サンプルA及びサンプルBにおけるフラジンの濃度をそれぞれ、6.42ppm及び11.06ppmと求めた。次いで、サンプルA及びサンプルBのキサンチンオキシダーゼ阻害活性を実施例1の方法により測定した。結果から、サンプルA及びサンプルBのXOI活性がそれぞれ51%及び75%であったことが分かる。結果から、サンプルにおけるフラジン濃度が高いほど、サンプルが有するXOI活性が高くなることが分かる。
2つの追加のフラジン試験サンプル(サンプルC及びサンプルD)を準備し、サンプルC及びサンプルDにおけるフラジンの量をHPLC分析により測定した。結果から、サンプルC及びサンプルDにおけるフラジンの濃度がそれぞれ6.42ppm及び7.05ppmであったことが分かる。次いでサンプルC及びサンプルDのキサンチンオキシダーゼ阻害活性を実施例1の方法により測定した。結果から、サンプルC及びサンプルDのキサンチンオキシダーゼ阻害活性がそれぞれ51%及び56%であったことが分かる。結果から、サンプルにおけるフラジン濃度が高いほど、サンプルが有するXOI活性が高くなることが分かる。
XOI活性が異なる9つのフラジンサンプルを分析することで、フラジン濃度及びキサンチンオキシダーゼ阻害活性を測定した。結果を図2に示す。サンプル番号4が最大のフラジン濃度及び最大のキサンチンオキシダーゼ阻害活性を示す。フラジン濃度が50ppm未満のサンプルは30%未満のキサンチンオキシダーゼ阻害活性を示す。結果からフラジン濃度(X;ug/10mg)とキサンチンオキシダーゼ阻害活性(Y;%)とに正の相関があることが分かる。フラジン濃度とキサンチンオキシダーゼ阻害活性との相関関係を図3に示す。フラジン濃度とキサンチンオキシダーゼ阻害活性との相関関係を示す指数方程式は下記のとおりに得られた。
Y=9.11ln(X)−4.64、R2=0.8348
本明細書で開示された特徴は全てあらゆる組合せで組み合わせることができる。本明細書で開示される各特徴は同じ、同等の、又は同様の目的を果たす代替特徴に置き換えることができる。そのため特に明記しない限り、開示される各特徴は一連の包括的な同等又は同様の特徴の例にすぎない。
Claims (15)
- キサンチンオキシダーゼ活性の阻害を必要とする対象においてキサンチンオキシダーゼ活性を阻害する方法であって、式(I):
- R1がカルボキシル基及び水素からなる群から選択される、請求項1に記載の方法。
- R1が水素であり、R2が水素である、請求項1に記載の方法。
- 前記化合物が1−[5−(ヒドロキシメチル)フラン−2−イル]−9H−ピリド[3,4−b]インドール−3−カルボン酸、及び/又は1−(5−ヒドロキシメチル−2−フリル)−β−カルボリン−3−カルボン酸である、請求項1に記載の方法。
- 尿酸値の低減を必要とする対象において尿酸値を低減する方法であって、該対象に有効量の式(I):
- 前記尿酸値の低減を必要とする対象が痛風又は高尿酸血症を患っている、請求項5に記載の方法。
- 前記化合物が経口投与される、請求項5に記載の方法。
- 前記化合物が純粋な形態である、請求項5に記載の方法。
- キサンチンオキシダーゼ阻害活性をモニタリングする方法であって、
(a)キサンチンオキシダーゼ阻害活性の所望レベルと相関する量である、式(I):
(b)モニタリングされる組成物群における前記β−カルボリンアルカロイド化合物の量を測定することと、
(c)前記量が前記所望量以上である場合に前記群が前記所望のキサンチンオキシダーゼ阻害活性に達していると判断することと、
を含む、方法。 - R1がカルボキシル基及び水素からなる群から選択される、請求項9に記載の方法。
- R1が水素であり、R2が水素である、請求項9に記載の方法。
- 前記化合物が1−[5−(ヒドロキシメチル)フラン−2−イル]−9H−ピリド[3,4−b]インドール−3−カルボン酸、及び/又は1−(5−ヒドロキシメチル−2−フリル)−β−カルボリン−3−カルボン酸である、請求項9に記載の方法。
- 前記β−カルボリンアルカロイド化合物の量が高速液体クロマトグラフィー(HPLC)により測定される、請求項9に記載の方法。
- モニタリング対象の前記組成物が発酵産物である、請求項9に記載の方法。
- モニタリング対象の前記組成物が希釈されている、請求項9に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562264933P | 2015-12-09 | 2015-12-09 | |
US62/264,933 | 2015-12-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017114851A true JP2017114851A (ja) | 2017-06-29 |
JP6472428B2 JP6472428B2 (ja) | 2019-02-20 |
Family
ID=59018794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016234432A Active JP6472428B2 (ja) | 2015-12-09 | 2016-12-01 | キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170165239A1 (ja) |
JP (1) | JP6472428B2 (ja) |
KR (1) | KR101846096B1 (ja) |
CN (1) | CN106983748B (ja) |
TW (1) | TWI627955B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102476098B1 (ko) | 2019-09-06 | 2022-12-09 | 한국교통대학교 산학협력단 | 결정성 테트라하이드로-베타-카볼린의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1970559A (zh) * | 2006-12-06 | 2007-05-30 | 中国科学院昆明植物研究所 | β-咔啉生物碱及其制备方法与应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5936919B2 (ja) * | 1978-10-14 | 1984-09-06 | 日本新薬株式会社 | インド−ル誘導体 |
WO2001068648A1 (en) * | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
PL1831227T3 (pl) * | 2004-12-17 | 2013-10-31 | Glenmark Pharmaceuticals Sa | Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych |
WO2007009485A1 (en) * | 2005-07-22 | 2007-01-25 | Pharma C S.A. | Substituted 8-phenoxy-y-carboline derivatives with 5ht1 activity |
WO2009067233A1 (en) * | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
WO2010034110A1 (en) * | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
US8497276B2 (en) * | 2009-03-31 | 2013-07-30 | Arqule, Inc. | Substituted indolo-piperidine compounds |
-
2016
- 2016-12-01 JP JP2016234432A patent/JP6472428B2/ja active Active
- 2016-12-06 US US15/370,527 patent/US20170165239A1/en not_active Abandoned
- 2016-12-06 KR KR1020160165312A patent/KR101846096B1/ko active IP Right Grant
- 2016-12-07 CN CN201611114970.XA patent/CN106983748B/zh active Active
- 2016-12-08 TW TW105140650A patent/TWI627955B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1970559A (zh) * | 2006-12-06 | 2007-05-30 | 中国科学院昆明植物研究所 | β-咔啉生物碱及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
J. AGRIC. FOOD CHEM., 2012, VOL.60, NO.39, PP.9856-9862, JPN6017036639 * |
Also Published As
Publication number | Publication date |
---|---|
TW201720441A (zh) | 2017-06-16 |
JP6472428B2 (ja) | 2019-02-20 |
KR101846096B1 (ko) | 2018-04-05 |
KR20170068387A (ko) | 2017-06-19 |
TWI627955B (zh) | 2018-07-01 |
US20170165239A1 (en) | 2017-06-15 |
CN106983748A (zh) | 2017-07-28 |
CN106983748B (zh) | 2019-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6127034B2 (ja) | 抗炎症性ピラゾロピリミジン | |
AU2012327210B2 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
JP7116063B2 (ja) | 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類 | |
JP2021521200A (ja) | 癌の処置のための化合物 | |
Yanes et al. | Postmenopausal hypertension: role of 20-HETE | |
Huang et al. | Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension | |
ES2630712T3 (es) | Nuevos compuestos de piridazinona y piridona | |
JP2019503395A (ja) | ピロロピリミジン5員環アザ環状誘導体およびその利用 | |
EA025106B1 (ru) | Бициклические пиримидиновые соединения | |
JP2021073257A (ja) | 疼痛の治療 | |
Ganesh et al. | Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists | |
WO2017223260A1 (en) | Pu.1 inhibitors | |
TWI688565B (zh) | 萘啶二酮(naphthyridinedione)衍生物 | |
JP6472428B2 (ja) | キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用 | |
ES2886571T3 (es) | Inhibidores y sus usos | |
US20210094907A1 (en) | Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy | |
Yang et al. | Discovery of 4-oxo-N-phenyl-1, 4-dihydroquinoline-3-carboxamide derivatives as novel anti-inflammatory agents for the treatment of acute lung injury and sepsis | |
ES2746310T3 (es) | Nuevo compuesto terapéutico y uso en terapia | |
JP2008110935A (ja) | 2−フェニルベンゾイミダゾール誘導体を有効成分とするstat6活性化阻害剤 | |
TWI225400B (en) | Prodrugs to D-prolines | |
TW201406759A (zh) | Vegfr-3抑制劑於治療肝細胞癌之用途 | |
WO2020004404A1 (ja) | IL-1β阻害薬 | |
JP5569816B2 (ja) | イミダゾール誘導体 | |
US20050131028A1 (en) | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders | |
WO2023174377A1 (zh) | 一种四环类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170926 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6472428 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |